The mechanisms by which b cell mass is reduced in patients with type 2 diabetes remain unclear. It has been postulated that ectopic fat deposits in the pancreas induce b cell apoptosis, leading to the development of diabetes.
T ype 2 diabetes (T2DM) is characterized by a deficit of b cell mass (1) (2) (3) (4) . Although it has been reported that the deficit of b cell mass in patients with T2DM is attributable to an increase in b cell apoptosis (1) , the mechanisms that cause b cell apoptosis remain uncertain.
Obesity is an established risk factor for T2DM (5, 6) . When fat supply exceeds the capacity of subcutaneous fat storage, spilled-over fat leads to ectopic fat deposits in not only visceral adipose tissue, but also various organs, including the pancreas (7, 8) . It has been reported that fatty acids induce b cell apoptosis in in vitro and in vivo studies of rodents (9, 10) , the so-called lipotoxicity hypothesis. In Zucker Diabetic Fatty rats, b cell dysfunction and apoptosis were accompanied by excess lipid accumulation in islets, suggesting that excess lipid accumulation in the pancreas induces b cell apoptosis (9, 10) .
However, conflicting results regarding the relationship between pancreatic fat content and b cell function or dysglycemia have been shown in human studies (7, (11) (12) (13) . Although pancreatic fat content measured by magnetic resonance imaging or magnetic resonance spectrometry (MRS) has been shown to correlate with b cell function and/or dysglycemia (14-16), we have previously reported no significant difference in pancreatic fat content measured by computed tomography (CT) imaging between subjects with and without T2DM (17) .
One of the major reasons for this inconsistency may be the difficulty of measurement of pancreatic fat content. Because the pancreas is surrounded by fat tissue in the retroperitoneal space, it is difficult to precisely exclude the fat outside the pancreas. Although attempts to improve the accuracy of pancreatic fat measurement using imaging tools have been made (14, 18, 19) , it remains impossible to completely distinguish interlobular fat (i.e., fat outside the pancreas) from intralobular fat of the pancreas due to the intricate lobular structure of the pancreas. Moreover, in contrast to the liver, in which fat is diffusely distributed within hepatocytes, pancreatic fat is mainly present in adipocytes within the pancreas (20) , and thereby the distribution of fat is not homogeneous within the pancreas, which accounts for the difficulty of assessment of pancreatic fat content by imaging methods.
In view of these limitations of imaging studies, we conducted a histological evaluation of intrapancreatic fat content using pancreas samples from 72 autopsy cases and 50 patients with and 49 without diabetes who underwent pancreatic surgery in an attempt to gain more insight into the relationship between pancreatic fat and b cell mass and diabetes.
Research Design and Methods

Subjects
This study was approved by the Ethics Committee of the Keio University School of Medicine. The cases have been reported in our prior studies (3, 21) . For autopsy cases, specimens of pancreas obtained at autopsy were acquired with the permission of the bereaved families. For patients who underwent pancreatic surgery, written informed consent was obtained from each patient, whereas it was waived for patients who had discontinued hospital visits at the time of study enrollment (n = 40).
A total of 72 autopsy cases without diabetes [nondiabetic (NDM)-1 group] and 99 patients who underwent pancreatic surgery [50 diabetic (DM) patients and 49 patients without diabetes (NDM-2 group)] were included in this study. The characteristics of the cases, which have been previously reported (3, 21) , are summarized in Table 1 . All subjects were Japanese.
Autopsy cases
Potential cases were first identified by retrospective analysis of the Keio University autopsy database. To be included, cases were required to have (1) been aged 20 to 69 years, (2) had a full autopsy within 24 hours of death, (3) medical information prior to death, (4) no history of diabetes, pancreatitis, pancreatic tumor, or pancreatic surgery, (5) no use of glucocorticoids, and (6) pancreatic tissue stored that was of adequate size and quality. Cases were excluded if pancreatic tissue had undergone autolysis.
Surgical cases
As previously described (3), subjects who underwent pancreatic surgery and whose resected pancreas sample contained adequate normal pancreas for histological analysis were included in the study. Of these, 41 patients had been diagnosed with T2DM before the diagnosis of pancreatic tumors, and eight patients were diagnosed with pancreatic cancer and diabetes at the same time. There was no case of type 1 diabetes or case in which glutamic acid decarboxylase antibody was positive.
Glycemic markers
In autopsy cases, glycated hemoglobin (HbA1c) measured within 1 year prior to death was obtained from the medical records (21) . In patients who underwent pancreatic surgery, information including HbA1c, casual plasma glucose, and serum C-peptide immunoreactivity levels was obtained from the medical records, as previously described (3). HbA1c was measured by high-performance liquid chromatography and expressed as National Glycohemoglobin Standardization Program and International Federation of Clinical Chemistry values. Serum C-peptide immunoreactivity was measured by chemiluminescent enzyme immunoassay. 
Pancreatic tissue processing
The pancreas was fixed in formaldehyde and then embedded in paraffin for subsequent analysis. Autopsy specimens were sampled from the body or tail portion of the pancreas, except for seven specimens sampled from the head of the pancreas. Seventy-nine and 20 surgical specimens were sampled from the body or tail portion and the head portion, respectively. Fivemicrometer sections were cut from the tumor-free region and stained for light microscopy as follows: (1) with hematoxylineosin, (2) for insulin (peroxidase staining) with hematoxylin, (3) for glucagon with hematoxylin, (4) for insulin and Ki67 for assessment of b cell replication, and (5) for insulin and singlestranded DNA or cleaved poly(adenosine 5 0 -diphosphateribose) polymerase-1 for assessment of b cell apoptosis, as previously described (3, 21) .
Morphometric analysis
As previously described (3, 21, 22) , to quantify fractional b cell area (BCA), the entire pancreatic section was imaged at 3200 magnification (320 objective) using a Mirax Scan and Mirax Viewer (Carl Zeiss MicroImaging GmbH, Göttingen, Germany). The ratio of BCA to total pancreas area was digitally measured using Image Pro Plus software (Media Cybernetics, Silver Springs, MD). Likewise, the ratio of a cell area (ACA) to total pancreas area was also digitally measured, and the ratio of ACA to BCA was determined in each case. Intraobserver coefficient of variance (computed in five cases studied on five occasions) and interobserver variance were approximately 7% and 12%, respectively (3, 21) . All measurements were conducted twice, and the mean of the two measurements was used.
To conduct further morphometric analysis, scattered b cells, insulin-positive duct cells, and b cell replication were quantified in randomly selected areas of the pancreas that contained more than 100 islets in each case, using a Mirax Viewer (Carl Zeiss MicroImaging GmbH). Scattered b cells were defined as a cluster of three or fewer b cells in acinar tissue, and the density of scattered b cells was determined as the number of scattered b cells/pancreas area (mm 2 ). Likewise, the density of islets and individual islet size were also determined in the same area. Insulin-positive duct cells were also counted and expressed as the number of insulin-positive duct cells/pancreas area (mm 2 ). The frequency of b cell replication was expressed as the percentage of islets.
Assessment of intrapancreatic fat content
Intrapancreatic fat content was graded based on histological evaluation [none (-) to severe (+++)] (Fig. 1) . Because pancreatic fat is extracted during specimen dehydration, intrapancreatic fat appears as lobulated spaces within the pancreas lobes. These intrapancreatic adipocytes were confirmed by perilipin staining (antiperilipin A antibody-carboxyterminal end; ab61682, Abcam, Cambridge, United Kingdom). These intrapancreatic fat areas (IPFAs) were also quantified using Image Pro Plus software (Media Cybernetics). Only pancreatic fat within parenchymal tissue (i.e., intralobular fat), but not interlobular fat (i.e., fat outside the pancreas), was measured as IPFA. Thus, IPFA was calculated as a fraction of total pancreatic area.
Statistical analysis
Data are presented as mean 6 standard deviation (SD) in the text and tables unless otherwise indicated. Non-normally distributed data are presented as median and interquartile range (IQR). Mann-Whitney U test was used to assess differences between two groups, and comparisons among the three groups were performed by Kruskal-Wallis test. Spearman correlation analysis was carried out for correlation analysis. Multivariate analysis was used to adjust for confounding factors such as age and body mass index (BMI). All analyses were performed using the Statistical Package for the Social Sciences (version 23; SPSS, Chicago, IL), and P , 0.05 was considered statistically significant.
Results
Intrapancreatic fat content in subjects with and without diabetes
Intrapancreatic adipocytes were diffusely distributed within the pancreatic lobes, and as the number of adipocytes increased, they formed clusters, which were readily distinguishable from other structures such as vessels, ducts, and interlobular adipocytes (Fig. 1) . Adipocytes were not observed within the islets. Histological grade of intrapancreatic fat content was closely correlated with IPFA (Table 2) . IPFA varied among subjects (median, 0.51%; IQR, 0.17% to 1.27%). There was no difference in IPFA between samples from the head portion of the pancreas (n = 27) and those from the body or Although we previously reported a significant reduction in BCA in patients with diabetes compared with age-and BMI-matched patients without diabetes (NDM-2) (1.48% 6 1.08% vs 0.80% 6 0.54%, P , 0.001) (3), there was no difference in IPFA between the two groups (median, 0.51%; IQR, 0.04% to 3.27% vs median, 0.61%; IQR, 0.03% to 5.83%; P = 0.53) [ Fig. 2(a) ]. In view of the fact that there was no significant difference in intrapancreatic fat content either between autopsy and surgical cases or between cases with and without diabetes, we conducted subsequent analyses in the combined cases as well as within each group.
Factors associated with intrapancreatic fat content
Characteristics of the subjects according to the histological grade of intrapancreatic fat content are shown in Table 2 and Supplemental Table 1 for surgical cases. Histological grade of intrapancreatic fat content was associated with age and BMI, but not with HbA1c or plasma glucose level. As well as histological grade, IPFA was significantly correlated with age and BMI in the total cases (both r = 0.20, P , 0.01) [ Fig. 2 (c) and 2(d)], but not with HbA1c [ Fig. 2(b) ]. In surgical cases, the duration of obesity as well as current BMI, but not maximum BMI, tended to associate with intrapancreatic fat content (P = 0.07 and 0.66, respectively) (Supplemental Table 1 ). The results were not markedly changed when the analysis was conducted only in the DM group (Supplemental Table 2 ). There was no significant correlation between IPFA and casual plasma glucose or serum C-peptide immunoreactivity level (Supplemental Table 2 ; Supplemental  Fig. 1 ).
Relationships between intrapancreatic fat content and BCA, ACA, and islet morphology There was no difference in either BCA or ACA among the groups according to the histological grade of intrapancreatic fat content [ Fig. 3(a) and 3(b) ], and there was no significant correlation between IPFA and BCA or ACA (r = 0.05, P = 0.56 and r = -0.12, P = 0.12) [ Fig. 3(f) and 3(g) ]. ACA/BCA ratio was also not associated with histological grade or IPFA [ Fig. 3(c) and  3(i) ]. When the NDM-1, NDM-2, and DM groups were analyzed separately (Supplemental Table 2 ), BCA and ACA were positively correlated with IPFA in the DM group (r = 0.30, P = 0.04 and r = 0.30, P = 0.04, respectively), and ACA was negatively correlated with IPFA in the NDM-1 group (r = -0.28, P = 0.02). However, the significant correlations were attenuated after adjustment for age and BMI (Supplemental Table 2 ).
Difference in mean islet size was also statistically significant among the histological grading groups (P = 0.03) [ Fig. 3(e) ], but no association between IPFA and mean islet size was detected (r = 0.00, P = 0.99) [ Fig. 3(j) ]. These results were not changed when the analyses were conducted in each group separately (i.e., NDM-1, NDM-2, and DM groups) (Supplemental Table 2 ). There was no association between IPFA and islet density (r = -0.10, P = 0.21) [ Fig. 3(i) ].
Relationships between intrapancreatic fat content and markers of b cell turnover
Intrapancreatic fat content assessed as histological grade or IPFA was not associated with either frequency of b cell replication, insulin-positive duct cells, or scattered b cells (Fig. 4) . No b cell apoptosis was observed in these cases, as previously reported (3, 21).
Discussion
The current study, applying histological evaluation of intrapancreatic fat content, showed the following: (1) There was no significant difference in intrapancreatic fat content between subjects with and without diabetes. (2) No association between intrapancreatic fat content and b cell mass, islet morphology, or markers of b cell turnover was observed. (3) There was no correlation between intrapancreatic fat content and HbA1c level. (4) Intrapancreatic fat content increased with age and obesity in humans.
T2DM is characterized by a deficit of b cells, presumably due to an increase in b cell apoptosis (1). However, the mechanisms by which b cell apoptosis increases in patients with T2DM remain unclear. A longitudinal cohort in the UK Prospective Diabetes Study suggested that b cell dysfunction begins over 10 years before the onset of T2DM (23) . Reduced b cell mass in patients with prediabetes has also been reported (1, 24, 25) , suggesting that b cell loss occurs even before the onset of T2DM.
Ectopic fat deposits are a hallmark of metabolic syndrome and T2DM (8, 26) . Rodent studies have suggested the possibility that ectopic fat deposits in the pancreas induce b cell apoptosis and the development of hyperglycemia (9, 10), the so-called lipotoxicity hypothesis. Since then, the association between pancreas fat content and b cell function or glucose tolerance status has been actively investigated (7, (11) (12) (13) .
Tushuizen et al. (14) first reported, using MRS, that pancreatic fat content was increased in patients with T2DM, and pancreatic fat content was negatively associated with b cell function in NDM subjects. However, the small sample size (12 with T2DM, 24 without diabetes) with an almost significant difference in BMI between the two groups has been pointed out as a limitation of that study (27) . We have previously reported, using CT scan images of over 2000 subjects, that there was no significant difference in pancreas fat content between age-, sex-, and BMI-matched subjects with and without T2DM (17). Furthermore, these inconsistent results of imaging studies may be in part due to difficulties in accurate measurement of pancreatic fat (11) . The pancreas is surrounded by fat in the retroperitoneal space and consists of an intricate lobular structure, making it inevitably difficult to distinguish intrapancreatic fat from fat outside the pancreas. In this study, to overcome these limitations of imaging studies, by conducting histological assessment of intrapancreatic fat content, we reported that there was no relationship between intrapancreatic fat content and b cell mass or dysglycemia in humans.
Our findings are also in line with prior histological studies assessing pancreas fat in subjects with diabetes, which have shown no difference in pancreatic fat content in subjects with and without T2DM (17, 20, 28, 29) . Our study applied quantification of intrapancreatic fat content in a relatively large number of subjects with a wide range of age and BMI, and we believe our findings are more objective and robust compared with those of these prior histological studies. Our conclusion that there is no association between intrapancreatic fat content and diabetes is also supported by the finding of no association between intrapancreatic fat content and b cell mass.
Recent rodent studies have suggested that dedifferentiation of b cells and conversion from b to a cells is one of the mechanisms of b cell loss in T2DM (30) , although histological studies in humans have suggested that b cell dedifferentiation has only a minor role, and presumably b cell apoptosis is a major cause of b cell loss in patients with T2DM (31), in line with the observation of reduced islet size in patients with T2DM (3, 32, 33) . In this study, we found no significant relationship between IPFA and either BCA or ACA/BCA ratio, suggesting that intrapancreatic fat content is unlikely to be associated with this intriguing possibility.
Recently, several studies showing no association between pancreatic fat and T2DM have also been published. Begovatz et al. (18) conducted an assessment of intrapancreatic fat by magnetic resonance imaging/MRS in 56 subjects with and without dysglycemia. In that https://academic.oup.com/jcemstudy, they measured intrapancreatic fat carefully after excluding the fat outside the pancreas and found no association between intrapancreatic fat content and b cell function or dysglycemia (18) . Yamazaki et al. (34) conducted a longitudinal study showing that pancreatic fat assessed by CT imaging was not associated with the development of T2DM independently of obesity. Moreover, whereas it has been reported that the improvement of dysglycemia by a very low-calorie diet in adults with T2DM was associated with improvement of pancreatic fat content (35), Gow et al. (36) did not find such an association between pancreatic fat and improvement of hyperglycemia during treatment with a very low-calorie diet in young people with T2DM. Taking these results together, to date, there is no concrete evidence for a causal association of pancreatic fat with the development of diabetes. Further studies to improve the accuracy of intrapancreatic fat measurement in vivo in humans are warranted. Also, because intra-and interlobular pancreatic fat content are both increased with aging and obesity, future studies should be carefully conducted to exclude these important confounders.
As with other studies, our study was not free from limitations. First, we assessed intrapancreatic fat in a section of the pancreas. Intrapancreatic fat content may differ among different portions of the pancreas. However, it has been reported that the proportion of fat content did not differ among the head, body, and tail portions of the pancreas (37, 38), and we found no significant difference in IPFA between samples from the head of the pancreas and those from the body or tail of the pancreas [Supplemental Fig. 2(a) ]. Also, the results did not change when the analyses were conducted using only samples from the body or tail of the pancreas (n = 144, data not shown). It should also be noted that b cell mass was assessed as fractional BCA in a section of the pancreas, although it is widely used as a measure of b cell mass, as discussed previously (3, 21) . Nonetheless, it should be kept in mind that the individual values may not be truly representative for any particular pancreas, although we believe that the overall conclusions are valid because of the large number of subjects studied. Whereas increased pancreatic fat infiltration has been reported in patients with pancreatic ductal adenocarcinoma (39), we found no significant difference in IPFA between patients with and without pancreatic cancer (median, 0.57%; IQR, 0.33% to 1.14% vs median, 0.56%; IQR, 0.20% to 1.35%; P = 0.94) [Supplemental Fig. 2(b) ]. Second, the histological measurement of fat was indirect, because fat is removed during tissue processing and section staining. However, the morphological features of adipocytes were readily identified, and we also confirmed the presence of adipocytes in the pancreas by perilipin staining (Fig. 1) .
We also assessed the intrapancreatic fat content using a grading system and confirmed consistent results between the two methods. Although we did not assess lipid content within islets, close correlations among IPFA, pancreatic triacylglycerol content (20) , and islet triacylglycerol content (9) have been reported in rodent models. Thus, it is reasonable to assume that IPFA reflects islet triglyceride content. Third, we could not assess b cell function in most of the subjects. Thus, although we found no association between IPFA and BCA, we cannot exclude the possibility that IPFA is associated with b cell dysfunction. However, the absence of association between IPFA and HbA1c, C-peptide immunoreactivity, or presence of diabetes suggests that the effect of IPFA on b cell function is, if any, modest. Although we could not exclude the possibility that patients with pancreatic diabetes, but not T2DM, were included in this study, we found no significant difference in IPFA between subjects with duration of diabetes #3 years (n = 23) and those with duration of diabetes .3 years (n = 26; median, 0.61%; IQR, 0.17% to 1.53% vs median, 0.59%; IQR, 0.26% to 1.71%; P = 0.41). Finally, this study included only Japanese subjects. We have reported that there was no significant correlation between b cell mass and BMI in Japanese subjects with and without T2DM (3, 21) , suggesting that the adaptive increase in b cell mass in response to obesity is minimal in the Japanese population. Thus, our findings may not be applicable to other ethnicities, and future studies including multiple ethnic groups are needed.
In conclusion, there was no correlation between intrapancreatic fat content and b cell mass or turnover, or dysglycemia. These findings suggest that ectopic fat deposits in the pancreas may not be responsible for the development of diabetes in humans.
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